跳到正文
原文
Nature 健康护理主题·· 24 天前AI 评分20

阿片类使用障碍药物治疗中渴求结局线性混合效应分析的模型选择

Model selection in linear mixed-effects analysis of craving outcomes in a randomized controlled trial of medications for opioid use disorders

AI 导读

基于NCT02032433随机对照试验数据(BUP-NX组n=287,XR-NTX组n=283),对阿片、酒精、兴奋剂及尼古丁渴求的纵向分析显示,非结构化(UN)协方差结构在AIC比较中拟合最优。随访期间四种渴求评分均较基线显著下降,且兴奋剂渴求在特定访视存在治疗组间交互效应。

正文

Scientific Reports (2026) Cite this article

We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.

Abstract

Identifying an appropriate covariance structure is a critical step in modeling longitudinal changes in polysubstance cravings during medications for opioid use disorders (MOUD) treatment. This study analyzed data from the National Drug Abuse Treatment Clinical Trials Network trial CTN0051, in which participants with opioid use disorders (OUDs) were randomized to receive either buprenorphine-naloxone (BUP-NX; n = 287) or extended-release naltrexone (XR-NTX; n = 283). Cravings for opioids, alcohol, stimulants, and nicotine were assessed at baseline and every four weeks over 36 weeks. Repeated-measures linear mixed models (LMMs) were used to examine longitudinal craving trajectories, with treatment, visit, and treatment-by-visit interaction specified as fixed effects and within-participant correlations among repeated observations modeled through the residual (R-side) covariance structure. Ten commonly used covariance structures were compared using Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) to determine optimal model fit. AIC-based comparisons indicated that the unstructured (UN) covariance structure provided the best fit for alcohol, opioid, and stimulant cravings and the second-best fit for nicotine craving. Using the UN covariance structure, craving scores decreased significantly from baseline across all four craving domains during follow-up. Treatment-by-visit interactions were observed for stimulant craving at selected visits, indicating differences between treatment groups in changes from baseline over time. Baseline alcohol and amphetamine use disorders predicted higher alcohol cravings, while baseline depression, amphetamine, and cocaine use disorders predicted greater stimulant cravings; baseline cocaine use disorder also predicted elevated nicotine craving. In conclusion, the UN covariance structure most effectively captured craving trajectories. These findings identify clinical characteristics associated with differences in reported craving; however, their utility for guiding treatment selection or predicting relapse requires prospective validation.

Clinical trial number: NCT02032433.

Abbreviations

AIC:

Akaike Information Criterion

AL:

Alcohol craving

ANTE:

Ante-dependence

AR:

Autoregressive

ARH:

Heterogeneous autoregressive

ARMA:

First-order autoregressive moving average

AUD:

Alcohol use disorder

BIC:

Bayesian Information Criterion

BUP-NX:

Buprenorphine-naloxone

CBT:

Cognitive-behavioral therapy

CDC:

Centers for Disease Control and Prevention

CS:

Compound symmetry

CSH:

Heterogeneous compound symmetry

CTN:

Clinical Trials Network

HF:

Huynh–Feldt

LMMs:

Linear mixed-effects models

MDD:

Major depressive disorder

MOUD:

Medications for opioid use disorders

NIC:

Nicotine craving

NIDA:

National Institute on Drug Abuse

OP:

Opioids craving

OUD:

Opioid use disorder

SD:

Standard deviation

STM:

Stimulant craving

SUD:

Substance use disorder

TOEP:

Banded Toeplitz

UN:

Unstructured

VAS:

Visual analog scales

VC:

Variance components

XR-NTX:

Extended-release naltrexone

Acknowledgements

The information reported here results from secondary analyses of data from NIDA CTN-0051 (Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment), a clinical trial conducted by the NIDA Clinical Trials Network. NIDA databases and information are available at https://datashare.nida.nih.gov.

Funding

No funding source is given for the present paper.

Author information

Authors and Affiliations

  1. Department of Biobehavioral Health & Nursing Science, College of Nursing, University of South Carolina, 1601 Greene St, Columbia, 29208, SC, USA

    Kesheng Wang, Donna M. Kazemi, Pamela J. Wright & Phyllis A. Raynor

  2. Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, 921 Assembly St, Columbia, 29208, SC, USA

    Kesheng Wang & Jiajia Zhang

Authors

  1. Kesheng Wang
  2. Donna M. Kazemi
  3. Pamela J. Wright
  4. Phyllis A. Raynor
  5. Jiajia Zhang

Corresponding author

Correspondence to Kesheng Wang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

The original CTN-0051 study (Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment) was approved by the institutional review boards at participating sites, and participants provided written informed consent. The present secondary analysis was exempt from IRB review due to secondary data analysis using a publicly accessible database.

Consent for publication

Not applicable.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, K., Kazemi, D.M., Wright, P.J. et al. Model selection in linear mixed-effects analysis of craving outcomes in a randomized controlled trial of medications for opioid use disorders. Sci Rep (2026). https://doi.org/10.1038/s41598-026-77858-y

Download citation

  • Received: 07 February 2026

  • Accepted: 22 October 2026

  • Published: 27 October 2026

  • DOI: https://doi.org/10.1038/s41598-026-77858-y

Keywords

来源:Nature 健康护理主题 · nature.com